Congress:
EuroSafe Imaging 2018
Keywords:
Epidemiology, Cancer, Radiation safety, Radiation effects, Education, Fluoroscopy, CT, Nuclear medicine, Cardiac, Breast, Action 9 - Facilitation of research in advanced topics of radiation protection, Action 7 - Medical radiation protection research: MELODI, EURAMED, Radiotherapy techniques
Authors:
E. Cardis, G. Frija, European Institute for Biomedical Imaging Research (EIBIR), G. Frija
DOI:
10.1594/esi2018/ESI-0080
Background/introduction
The evolution of medical science and the growing pace of innovation and deployment of medical technology have led to a situation where most of the artificial ionising radiation exposure of the European population is due to medical procedures.
Though most exposures result in low to moderate doses in most tissues,
there is a need to evaluate their health effects and optimise dose reduction practices and dose evaluation tools.
MEDIRAD aims to enhance the scientific bases and clinical practice of radiation protection in the medical field and thereby address the need to better understand and evaluate the health effects of low-dose ionising radiation exposure from diagnostic and therapeutic imaging and from off target effects in radiotherapy (RT).
This 4-year project started on June 1,
2017 and brings together 33 partner institutions from 14 European countries.
The multi-disciplinary consortium includes clinical experts,
scientists and policy makers in the fields of medical,
radiation protection and nuclear research from hospitals,
universities and major research centres across Europe.
MEDIRAD is led by the European Institute for Biomedical Imaging Research – EIBIR (AT).
Prof.
Guy Frija (Paris Descartes University,
FR; chair of EuroSafe Imaging),
acts as Clinical Coordinator and Prof.
Elisabeth Cardis,
(ISGlobal,
ES),
as Scientific Coordinator of the project.